RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome
- Wednesday, July 14, 2021, 7:15
- PR Newswire
- Add a comment
ROCKVILLE, Md., July 14, 2021 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration has released an update from its U.S. joint venture, ReGenTree LLC, regarding its…